Autres langues Affimed N.V.

Actions

AFMD

NL0015001ZQ0

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 23/04/2024			Varia. 5j.	Varia. 1 janv.
5,35 ^USD	+7,00 %		-0,37 %	-14,40 %

01/04	AFFIMED N.V. : Wells Fargo Securities toujours positif	ZM
01/04	AFFIMED N.V. : HC Wainwright à l'achat	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology	10:05
Affimed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Affimed Reports 2023 Financial Results and Operational Progress	28/03
Affimed N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024	21/03
Affimed N : Form 6-K	11/03
Affimed Announces 1-for-10 Reverse Stock Split	06/03
AFFIMED ANNOUNCES LEADERSHIP CHANGE AND ORGANIZATIONAL RESTRUCTURING	09/01
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer	08/01
Affimed N.V. Provides Clinical Response Update on AFM24-102 Trial in EGFR-Wildtype Non-Small Cell Lung Cancer	08/01
Affimed Announces Leadership Change and Organizational Restructuring	08/01
Affimed N.V. Announces CEO Changes	08/01
Affimed N.V. Announces Management Changes	08/01
Sector Update: Health Care Stocks Mixed Late Afternoon	03/01
Sector Update: Health Care Stocks Gain in Afternoon Trading	03/01
Affimed to Sell AbCheck to Ampersand Biomedicines for $6 Million in Cash, Stock; Shares Fall	03/01
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck	03/01
Ampersand Biomedicines Inc. entered into a definitive agreement to acquire AbCheck s.r.o. from Affimed N.V. for $6.4 million.	03/01
Affimed N.V.(NasdaqCM:AFMD) dropped from NASDAQ Biotechnology Index	15/12
AFFIMED ANNOUNCES UPDATED PHASE DATA FROM ACIMTAMIG IN COMBINATION WITH ALLOGENEIC NK IN HODGKIN LYMPHOMA PATIENTS WHO FAILED PRIOR CHEMOTHERAPY AND ARE DOUBLE-REFRACTORY TO BRENTUXIMAB VEDOTIN AND CHECKPOINT INHIBITORS	12/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Affimed N.V.

Actions

AFMD

NL0015001ZQ0

Autres langues

Filtres